Loading clinical trials...

OFC rTMS in Emotionally Unstable and Depressed Patients | Clinical Trials | Clareo Health

COMPLETEDNA

OFC rTMS in Emotionally Unstable and Depressed Patients

Orbitofrontal Cortex Transcranial Magnetic Stimulation in Patients With Emotionally Unstable Personality Disorder and Depression

NCT04259554•University of Regensburg

View on ClinicalTrials.gov

Summary

Treatment of depression with conventional transcranial magnetic stimulation (rTMS) has shown high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation. Recently, it could be demonstrated that treatment of the right orbitofrontal cortex may be effective in patients who did not respond to conventional DLPFC rTMS. Orbitofrontal cortex (OFC) seem to be involved in the etiopathology of emotionally instable personality disorders. Thus, the present one-arm trial is a pilot study investigating if OFC rTMS is feasable, tolerable and effective.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•ICD-10: F60.30 or F60.31
•depressive symptoms and HAMD-21 score of at least 7
•sex: female and male
•residence in Germany and German speaking
•written informed consent

Exclusion Criteria

•meeting the contraindications for transcranial magnetic stimulation (electric devices or metal implants in the body, e.g. cardiac pace maker, insulin pump)
•neurological disorders (e.g. cerebrovascular events, neurodegenerative disorder, epilepsy, brain malformation, severe head trauma)
•participation in another study parallel to the Trial
•other mental or somatic illness which is not compatible with participation according to the principal investigator
•pregnancy or breastfeeding period
•psychiatric confinement

Locations (1)

University of Regensburg

Regensburg, Germany

Key Dates

Start Date

February 14, 2020

Primary Completion Date

July 1, 2022

Completion Date

October 1, 2022

Last Updated

December 9, 2022

Enrollment

ACTUAL participants

Conditions

Personality Disorder, BorderlinePersonality Disorder; UnstableDepression

Interventions

OFC rTMS

DEVICE

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

OFC rTMS in Emotionally Unstable and Depressed Patients

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures